Alberto Palazzuoli

Summary

Affiliation: University of Siena
Country: Italy

Publications

  1. Palazzuoli A, Ronco C. Cardio-renal syndrome: an entity cardiologists and nephrologists should be dealing with collegially. Heart Fail Rev. 2011;16:503-8 pubmed publisher
    ..Therapy addressed to improve renal dysfunction, reduce neurohormonal activation and ameliorate renal blood flow could lead to a reduction in mortality and hospitalization in patients with cardio-renal syndrome. ..
  2. Palazzuoli A, Beltrami M, Gennari L, Dastidar A, Nuti R, McAlindon E, et al. The impact of infarct size on regional and global left ventricular systolic function: a cardiac magnetic resonance imaging study. Int J Cardiovasc Imaging. 2015;31:1037-44 pubmed publisher
    ..A multi-parametric score measuring WMSI scar transmurality and extension, could better identify an increased cardiac remodeling after coronary event. ..
  3. Beltrami M, Ruocco G, Dastidar A, Franci B, Lucani B, Aloia E, et al. Additional value of Galectin-3 to BNP in acute heart failure patients with preserved ejection fraction. Clin Chim Acta. 2016;457:99-105 pubmed publisher
    ..However it is related to diastolic dysfunction severity and LV stiffness in HFpEF. Gal-3 demonstrates a prognostic role independently from renal dysfunction in subjects with HFpEF. ..
  4. Palazzuoli A, Testani J, Ruocco G, Pellegrini M, Ronco C, Nuti R. Different diuretic dose and response in acute decompensated heart failure: Clinical characteristics and prognostic significance. Int J Cardiol. 2016;224:213-219 pubmed publisher
    ..HD and poor DE are two conditions associated with adverse outcome. Both situations are the consequence of previous detrimental clinical status and they appear strictly related to WRF occurrence. ..
  5. Palazzuoli A, Ceccarelli E, Ruocco G, Nuti R. Clinical impact of oral antidiabetic medications in heart failure patients. Heart Fail Rev. 2018;: pubmed publisher
    ..In this review, we would analyze the specific effects of each class so as to better elucidate the clinical impact of antidiabetic drug on HF for guiding the clinicians in the choice of a best individualized therapy. ..
  6. Palazzuoli A, Rizzello V, Calabrò A, Gallotta M, Martini G, Quatrini I, et al. Osteoprotegerin and B-type natriuretic peptide in non-ST elevation acute coronary syndromes: relation to coronary artery narrowing and plaques number. Clin Chim Acta. 2008;391:74-9 pubmed publisher
    ..OPG increase seems related to the number of plaques in the coronary vessels, suggesting its involvement in the coronary disease progression. BNP is also increased during NSTE-ACS and more associated to coronary narrowing. ..
  7. Palazzuoli A, Gallotta M, Quatrini I, Nuti R. Natriuretic peptides (BNP and NT-proBNP): measurement and relevance in heart failure. Vasc Health Risk Manag. 2010;6:411-8 pubmed
    ....
  8. Palazzuoli A, Caputo M, Fineschi M, Navarri R, Calabrò A, Cameli M, et al. B-type natriuretic peptide as an independent predictor of coronary disease extension in non-ST elevation coronary syndromes with preserved systolic function. Eur J Prev Cardiol. 2012;19:366-73 pubmed publisher
    ..Circulating BNP levels appear elevated in NSTEMI-ACS, without left ventricular systolic dysfunction. A BNP cut-off value of 80?pg/ml is a good predictor of CAD extension. ..
  9. Beltrami M, Ruocco G, Ibrahim A, Lucani B, Franci B, Nuti R, et al. Different trajectories and significance of B-type natriuretic peptide, congestion and acute kidney injury in patients with heart failure. Intern Emerg Med. 2017;12:593-603 pubmed publisher
    ..03). BNP reduction in AHF is associated with decongestion. BNP reduction associated with decongestion at discharge is a favorable prognostic indicator at 90-day survival irrespective of the AKI occurrence. ..
  10. Palazzuoli A, Ruocco G, De Vivo O, Nuti R, McCullough P. Prevalence of Hyperuricemia in Patients With Acute Heart Failure With Either Reduced or Preserved Ejection Fraction. Am J Cardiol. 2017;120:1146-1150 pubmed publisher
    ..32 to 4.28; p = 0.004). In conclusion, in AHF hyperuricemia is common in both in HFrEF and in HFpEF. In the HFpEF subgroup, hyperuricemia was the only independent predictor of heart failure hospitalization or death. ..

Detail Information

Publications10

  1. Palazzuoli A, Ronco C. Cardio-renal syndrome: an entity cardiologists and nephrologists should be dealing with collegially. Heart Fail Rev. 2011;16:503-8 pubmed publisher
    ..Therapy addressed to improve renal dysfunction, reduce neurohormonal activation and ameliorate renal blood flow could lead to a reduction in mortality and hospitalization in patients with cardio-renal syndrome. ..
  2. Palazzuoli A, Beltrami M, Gennari L, Dastidar A, Nuti R, McAlindon E, et al. The impact of infarct size on regional and global left ventricular systolic function: a cardiac magnetic resonance imaging study. Int J Cardiovasc Imaging. 2015;31:1037-44 pubmed publisher
    ..A multi-parametric score measuring WMSI scar transmurality and extension, could better identify an increased cardiac remodeling after coronary event. ..
  3. Beltrami M, Ruocco G, Dastidar A, Franci B, Lucani B, Aloia E, et al. Additional value of Galectin-3 to BNP in acute heart failure patients with preserved ejection fraction. Clin Chim Acta. 2016;457:99-105 pubmed publisher
    ..However it is related to diastolic dysfunction severity and LV stiffness in HFpEF. Gal-3 demonstrates a prognostic role independently from renal dysfunction in subjects with HFpEF. ..
  4. Palazzuoli A, Testani J, Ruocco G, Pellegrini M, Ronco C, Nuti R. Different diuretic dose and response in acute decompensated heart failure: Clinical characteristics and prognostic significance. Int J Cardiol. 2016;224:213-219 pubmed publisher
    ..HD and poor DE are two conditions associated with adverse outcome. Both situations are the consequence of previous detrimental clinical status and they appear strictly related to WRF occurrence. ..
  5. Palazzuoli A, Ceccarelli E, Ruocco G, Nuti R. Clinical impact of oral antidiabetic medications in heart failure patients. Heart Fail Rev. 2018;: pubmed publisher
    ..In this review, we would analyze the specific effects of each class so as to better elucidate the clinical impact of antidiabetic drug on HF for guiding the clinicians in the choice of a best individualized therapy. ..
  6. Palazzuoli A, Rizzello V, Calabrò A, Gallotta M, Martini G, Quatrini I, et al. Osteoprotegerin and B-type natriuretic peptide in non-ST elevation acute coronary syndromes: relation to coronary artery narrowing and plaques number. Clin Chim Acta. 2008;391:74-9 pubmed publisher
    ..OPG increase seems related to the number of plaques in the coronary vessels, suggesting its involvement in the coronary disease progression. BNP is also increased during NSTE-ACS and more associated to coronary narrowing. ..
  7. Palazzuoli A, Gallotta M, Quatrini I, Nuti R. Natriuretic peptides (BNP and NT-proBNP): measurement and relevance in heart failure. Vasc Health Risk Manag. 2010;6:411-8 pubmed
    ....
  8. Palazzuoli A, Caputo M, Fineschi M, Navarri R, Calabrò A, Cameli M, et al. B-type natriuretic peptide as an independent predictor of coronary disease extension in non-ST elevation coronary syndromes with preserved systolic function. Eur J Prev Cardiol. 2012;19:366-73 pubmed publisher
    ..Circulating BNP levels appear elevated in NSTEMI-ACS, without left ventricular systolic dysfunction. A BNP cut-off value of 80?pg/ml is a good predictor of CAD extension. ..
  9. Beltrami M, Ruocco G, Ibrahim A, Lucani B, Franci B, Nuti R, et al. Different trajectories and significance of B-type natriuretic peptide, congestion and acute kidney injury in patients with heart failure. Intern Emerg Med. 2017;12:593-603 pubmed publisher
    ..03). BNP reduction in AHF is associated with decongestion. BNP reduction associated with decongestion at discharge is a favorable prognostic indicator at 90-day survival irrespective of the AKI occurrence. ..
  10. Palazzuoli A, Ruocco G, De Vivo O, Nuti R, McCullough P. Prevalence of Hyperuricemia in Patients With Acute Heart Failure With Either Reduced or Preserved Ejection Fraction. Am J Cardiol. 2017;120:1146-1150 pubmed publisher
    ..32 to 4.28; p = 0.004). In conclusion, in AHF hyperuricemia is common in both in HFrEF and in HFpEF. In the HFpEF subgroup, hyperuricemia was the only independent predictor of heart failure hospitalization or death. ..